Table 2 Angiographic characteristics at baseline and follow-up

From: Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation

  

ARB

 

Non-ARB (n=10)

Olmesartan (n=20)

Valsartan (n=20)

Baseline

   

 Vessel disease

   

1/2/3 (%)

60/30/10

45/20/35

55/15/30

 Target vessel

   

 LAD/LCX/RCA (%)

80/10/10

5/1/2

53/21/26

 Complex (B2/C) lesion (%)

90

75

70

 Stent type

   

BMS/DES (n)

30/70

35/65

45/55

 Pre-procedure

   

Lesion length (mm)

21±11

16±7

20±7

MLD (mm)

0.64±0.45

0.84±0.44

0.86±0.42

 Post-procedure

   

Reference diameter (mm)

2.67±0.64

2.72±0.64

2.83±0.53

Mean stent diameter (mm)

3.04±0.54

2.93±0.43

2.93±0.41

Mean stent length (mm)

29.6±13.4

23.1±9.8

24.9±7.6

In-stent % DS (%)

12.1±5.3

14.3±6.9

17.9±10.4

Follow-up

 Reference diameter (mm)

2.94±0.71

2.84±0.50

2.89±0.49

 In-stent late loss (mm)

0.47±0.61

0.21±0.59

0.26±0.80

 In-stent % DS (%)

34.4±16.7

26.8±10.6

30.1±13.9

  1. Abbreviations: BMS, bare metal stent; DES, drug eluting stent; LAD, left anterior descending artery; LCX, left circumflex coronary artery; MLD, minimal lumen diameter; DS, diameter stenosis; RCA, right coronary artery.
Back to article page